Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00182429
Status:
COMPLETED
Last Update Posted:
2018-08-15
First Post:
2005-09-13
Brief Title:
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
Sponsor:
McMaster University
Organization:
McMaster University
Study Overview
Official Title:
Prospective Randomized Study of Oral Metronidazole vs Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea CDAD
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
What is the difference between the use of one drug Oral Metronidazole versus the use of this same drug combined with another drug Rifampin in treatment of bacteria and infection-associated diarrhea in patients This infection is an important cause of morbidity and mortality in both the community and hospitals and the leading cause of hospital and chronic facility-acquired diarrhea Research is important for the treatment of this infection Patient care with use of two medication treatment regimens will be studied
Detailed Description:
Clostridium difficile infection contributes to both community and hospital acquired morbidity and mortality Metronidazole alone is usually considered the drug of choice however frequent relapses occur at a rate of 10-40 The purpose of this study is to address the use of a combined drug regimen treatment Metronidazole and Rifampin for the treatment of CDAD These drugs used together have been successful Objectives are to determine the time days to resolution of symptoms in each treatment arm to measure clinical relapse rates and to assess adverse reactions related to treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Grant Number R03-39 PSI | None | None | None |